Vivian Scheuplein - Max Delbruck Ctr Mol Med, Helmholtz Assoc

基本信息

浏览量：3

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 9 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

A Phase I Study of MAGE-A1-targeted T1367 T-cell Receptor-Based Cell Therapy in Patients with Advanced Multiple Myeloma

Josefine Krüger,Matthias Obenaus,Igor Wolfgang Blau,Dana Hoser,Martin Vaegler, Hana Rauschenbach,Ioannis Anagnostopoulos,Korinna Jöhrens,Vivian Scheuplein,Elisa Kieback, Judith Böhme,Ann-Christin von Brünneck,Jan Krönke,Antonia Busse,Gerald Willimsky,Thomas Blankenstein,Antonio Pezzutto,Ulrich Keller,Axel Nogai

Haematologicano. 1 (2025): 244-250

引用0浏览0WOS引用

Exploring MAGE-A1 As a Therapeutic Target in Advanced Multiple Myeloma: Expression Analysis and Phase 1 Clinical Trial of MAGE-A1-Directed TCR-1367 T Cells

Josefine Krueger,Matthias Obenaus,Igor Wolfgang Blau,Dana Hoser,Martin Vaegler, Hana Rauschenbach,Ioannis Anagnostopoulos,Korinna Joehrens,Vivian Scheuplein,Elisa Kieback, Judith Boehme,Ann-Christin Von Bruenneck,Jan Kroenke,Gerald Willimsky,Thomas Blankenstein,Antonio Pezzutto,Ulrich Keller,Axel Nogai

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2024): S64-S65

引用0浏览0引用

P-041 Exploring MAGE-A1 As a Therapeutic Target in Advanced Multiple Myeloma: Expression Analysis and Phase 1 Clinical Trial of MAGE-A1-Directed TCR-1367 T Cells

Josefine Krüger,Matthias Obenaus,Igor Wolfgang Blau,Dana Hoser,Martin Vaegler, Hana Rauschenbach,Ioannis Anagnostopoulos,Korinna Jöhrens,Vivian Scheuplein,Elisa Kieback, Judith Böhme,Ann-Christin von Brünneck,Jan Krönke,Gerald Willimsky,Thomas Blankenstein,Antonio Pezzutto,Ulrich Keller,Axel Nogai

Clinical Lymphoma Myeloma and Leukemia (2024): S64-S65

引用0浏览0引用

Targeting the Recurrent Rac1P29S Neoepitope in Melanoma with Heterologous High-Affinity T Cell Receptors

Lena Immisch,George Papafotiou, Nerea Gallarin Delgado,Vivian Scheuplein,Annette Paschen,Thomas Blankenstein,Gerald Willimsky

Frontiers in Immunology（2023）

引用2浏览0WOS引用

95 MAGE-A1 Protein Expression Pattern in > 5,000 Tumor and Healthy Tissue Samples: Validation of MAGE-A1 As an Ideal Target for TCR-based Cell Therapy

Ronald Simon,Thomas Blankenstein,Jennifer Oduro,Natalia Gorbokon,Christoph Fraune,Julia Bluhm,Vivian Scheuplein,Elisa Kieback,Matthias Obenaus,Eugen Leo

Regular and Young Investigator Award Abstracts (2021)

引用0浏览0引用

225 Optimal-affinity MAGE-A1-specific T Cell Receptors (tcrs) Generated Using the Humanized TCR-transgenic Mouse Platform HuTCR Are Superior to Human Donor-Derived TCRs

Ioannis Gavvovidis,Matthias Leisegang,Vivian Scheuplein,Matthias Obenaus,Thomas Blankenstein,Elisa Kieback

Journal for ImmunoTherapy of Cancerno. Suppl 2 (2021): A239-A239

引用0浏览0引用

In Vitro Proteasome Processing of Neo-Splicetopes Does Not Predict Their Presentation in Vivo

Gerald Willimsky,Christin Beier,Lena Immisch,George Papafotiou,Vivian Scheuplein,Andrean Goede,Hermann-Georg Holzhuetter,Thomas Blankenstein,Peter M. Kloetzel

eLife（2021）

引用12浏览0WOS引用

499 A First-in-human, Phase 1/2 Clinical Trial of TK-8001, a MAGE-A1 Directed T Cell Receptor in Patients with Advanced-Stage Solid Tumors (the “Imag1ne”-Trial)

Fiona Thistlethwaite,Antonia Busse,Emiliano Calvo, Marie-Luise Goebeler,Martin Wermke,Sylvie Rottey,Nuria Kotecki,Matthias Obenaus,Vivian Scheuplein, Ralf Wolter, Carolina Perdomo-Ortiz,Ioannis Gavvovidis,Elisa Kieback,Thomas Blankenstein,Eugen Leo

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021): A531-A531

引用0浏览0引用

MAGE-A1 PROTEIN EXPRESSION PATTERN IN > 5,000 TUMOR AND HEALTHY TISSUE SAMPLES: VALIDATION OF MAGE-A1 AS AN IDEAL TARGET FOR TCR-BASED CELL THERAPY

Jennifer Oduro,Ronald Simon,Natalia Gorbokon,Christoph Fraune,Julia Bluhm,Vivian Scheuplein,Elisa Kieback,Matthias Obenaus,Thomas Blankenstein,Eugen Leo

JOURNAL FOR IMMUNOTHERAPY OF CANCERno. Suppl 2 (2021): A104-A104

引用0浏览0引用

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn